Takeda Pharmaceutical Limited's Revenue in the fiscal year 2025 $ 30,079.37 millions
Takeda Pharmaceutical Limited's Revenue in the fiscal year 2024 $ 29,535.84 millions
Takeda Pharmaceutical Limited's Revenue in the fiscal year 2023 $ 29,793.78 millions
Takeda Pharmaceutical Limited's Revenue in the fiscal year 2022 $ 31,787.95 millions
Takeda Pharmaceutical Limited's Revenue in the fiscal year 2021 $ 30,165.89 millions
TAK Revenue fourth quarter 2025 Y/Y Growth Comment
Takeda Pharmaceutical Company Limited reported Revenue growth of 0.06% year on year in the fourth quarter 2025, to $ 29,183.90 millions, this is lower than Takeda Pharmaceutical Company Limited's recent average Revenue growth of 4.53%.
Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 109 other companies have achieved higher Revenue growth. While Takeda Pharmaceutical Company Limited' s Revenue increase of 0.06% ranks overall at the positon no. 1685 in the fourth quarter 2025.
Takeda Pharmaceutical Limited's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Mar 31 2025)
12 Months Ending (Mar 31 2024)
12 Months Ending (Mar 31 2023)
12 Months Ending (Mar 31 2022)
12 Months Ending (Mar 31 2021)
Cumulative Revenue 12 Months Ending
$ 30,079.37
$ 29,535.84
$ 29,793.78
$ 31,787.95
$ 30,165.89
Y / Y Revenue Growth (TTM)
1.84 %
-0.87 %
-6.27 %
5.38 %
-0.37 %
Year on Year Revenue Growth Overall
Ranking
# 1685
# 1585
# 0
# 0
# 0
Seqeuential Revenue Change (TTM)
1.84 %
-0.87 %
-6.27 %
5.38 %
-0.37 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 1685
# 1585
# 0
# 0
# 0
Cumulative Revenue growth Comment
Although Takeda Pharmaceutical Limited's Annual Revenue growth year on year were below company's average 4.53% , Revenue announced in the Mar 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 1.84% year on year, from -0.87% in Mar 31 2024.
In the Healthcare sector 305 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1585 to 1685.
Although Takeda Pharmaceutical Limited's Annual Revenue growth year on year were below company's average 4.53% , Revenue announced in the Mar 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 1.84% year on year, from -0.87% in Mar 31 2024.
In the Healthcare sector 305 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1585 to 1685.
About Takeda Pharmaceutical Limited Revenue Growth Rates (TAK), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
What’s included here
Company: Takeda Pharmaceutical Co Ltd
(CIK 1395064).
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
0.06%